- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03665675
Haplo-identieke donor CMV-specifieke CTL voor de behandeling van CMV-reactivering of infectie na vast orgaan en HCT
Pilotstudie van Haplo-identieke donorcytomegalovirus (CMV) specifieke cytotoxische T-lymfocyten (CTL) voor de behandeling van CMV-reactivering of -infectie na transplantatie van vaste organen en hematopoëtische stamcellen (HCT)
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific [AdV] specific CTLs) work in treating CMV or AdV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
PRIMARY OBJECTIVE I. Assess the safety and feasibility of administering virus specific-CTLs from haploidentical donors in transplant patients both solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT) with CMV/AdV infection despite standard therapy.
OUTLINE:Patients are assigned to 1 of 2 Cohorts.
COHORT A: Patients receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes intravenously (IV). Patients undergo blood, urine, saliva, cerebrospinal fluid (CSF), and bronchoalveolar fluid sample collection on the trial.
COHORT B: Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Patients undergo blood, urine, saliva, CSF, and bronchoalveolar fluid sample collection on the trial.
After completion of study treatment, participants are followed up at 1 year.
Studietype
Inschrijving (Geschat)
Fase
- Vroege fase 1
Contacten en locaties
Studiecontact
- Naam: The Ohio State University Comprehensive Cancer Center
- Telefoonnummer: 800-293-5066
- E-mail: OSUCCCClinicaltrials@osumc.edu
Studie Contact Back-up
- Naam: Nicole Szuminski
- Telefoonnummer: 614-688-9796
- E-mail: Nicole.Szuminski@osumc.edu
Studie Locaties
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43205
- Werving
- Nationwide Children's Hospital
-
Contact:
- Chris Ouellette, MD
-
Contact:
- Melinda Triplet, RN, BSN
- Telefoonnummer: 614-722-6039
- E-mail: Melinda.Triplet@nationwidechildrens.org
-
Columbus, Ohio, Verenigde Staten, 43210
- Geschorst
- Ohio State University Comprehensive Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Patients must have solid organ transplant or have received allogeneic hematopoietic stem cell transplant.
-
• Cohort A (CMV): Must have documented CMV disease or reactivation, as by:
-
Viremia as detected by quantitative polymerase chain reaction (PCR) (> 500 IU/ml) in the peripheral blood requiring treatment OR
-
High risk for antiviral failure due to history of recurrent CMV reactivations or evidence of antiviral drug resistance, OR
-
Unable to tolerate antiviral drugs due to renal toxicity, bone marrow suppression, transfusion dependent anemia and thrombocytopenia or neutropenia requiring growth factor support or other related organ injury
• Cohort B (AdV): Must have documented AdV infection or reactivation, as by:
-
Symptomatic subject with any detectable viral load in blood, OR
-
Symptomatic subject with qualitative AdV detection in compartment of current symptomatology, including stool, urine, and/or other specimens (bronchoalveolar lavage (BAL), nasal swab, CSF, etc.), irrespective of blood viral load, OR
-
New, persistent, and/or worsening AdV-related symptoms, signs, and/or markers of end organ compromise while receiving antiviral therapy (ie cidofovir), OR
-
Asymptomatic with a viral load > 1000 copies/ml in peripheral blood, OR
-
Unable to tolerate antiviral treatment due to renal toxicity, bone marrow suppression, transfusion dependent anemia and thrombocytopenia or neutropenia requiring growth factor support or other related organ injury
- Karnofsky (age > 16 years) or Lansky performance score > 70 (age < 16)
- Available seropositive haploidentical or matched donor who is without evidence of infection that would otherwise preclude donation
- Negative pregnancy test in female patients if applicable (childbearing potential, has not received a full-intensity conditioning regimen
- Written informed consent and/or signed assent line from patient, parent or guardian
- DONOR
- Human leukocyte antigen (HLA)-haploidentical or full-match to the patient as determined by institutional standards
- Cohort A: CMV seropositive, defined as detection of serum CMV immunoglobulin G (IgG)
- Cohort B: AdV seropositive, defined as detection of serum AdV IgG
- Age 18 or over
- Meet donor eligibility or suitability according to institutional standards. If the donor is deemed ineligible according to Foundation for the Accreditation of Cellular Therapy (FACT) standards, but is suitable for donation per institutional standards, the donor will be eligible for the protocol
-
Exclusion Criteria:
-
Receipt of anti-thymocyte globulin (ATG), alemtuzumab, or other T-cell depleting agents within 21 days of screening for enrollment.
-
Receipt of > 0.5mg/kg/day of prednisone or steroid equivalent at the time of enrollment. Stable GVHD is permitted as long as patients are on stable dose steroids of less than or equal to 0.5 mg/kg/day of prednisone or steroid equivalent.
-
Evidence of uncontrolled infection as follows:
- Bacterial infections - patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment.
- Fungal infections - patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment.
- Patients with hemodynamic instability attributable to bacterial sepsis or new symptoms, worsening physical signs or radiographic findings attributable to concomitant bacterial or fungal infection are excluded. Patients who require ventilator support for CMV pneumonitis are not excluded. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
-
Receipt of donor lymphocyte infusion (DLI) within 28 days.
-
Patients with active acute graft versus host disease (GvHD) grades II-IV requiring > 0.5 mg/kg/day of prednisone or steroid equivalent or T-cell depleting immunosuppression.
-
Acute graft rejection in solid organ transplantation requiring augmented immunosuppression with T-cell depleting agents or steroids as mentioned above.
-
Active and uncontrolled relapse of malignancy.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment (CMV-specific CTLs)
Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days. |
Given intravenously |
|
Experimenteel: Treatment (AdV-specific CTLs)
Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days. |
Given intravenously |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Haalbaarheid gedefinieerd als het identificeren van een geschikte donor binnen 4 weken en het voldoen aan minimale T-celdoses in het eindproduct
Tijdsspanne: Tot 1 jaar
|
Tot 1 jaar
|
|
|
Incidence of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events 4.0
Tijdsspanne: Up to 30 days post infusion
|
Measured as the proportion of patients with acute (a) graft versus host disease (GvHD) grades III-IV or graft rejection/failure within 30 days of the last dose of cytotoxic T-lymphocytes (CTLs) or grades 3-5 infusion-related adverse events within 7 days of the last does of CTLs or grades 4-5 non-hematological adverse events within 30 days of the last dose of CTLs and that are not due to the pre-existing infection or the original malignancy or pre-existing co-morbidities. Will be calculated by dividing by all evaluable patients and the corresponding 95% confidence intervals will be calculated. |
Up to 30 days post infusion
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Persistentie van geïnfundeerde CTL's zoals gemeten door herschikking van T-celgenen en effecten op klinische tekenen van virale infectie
Tijdsspanne: Tot 1 jaar
|
Tot 1 jaar
|
|
|
Effecten van cytomegalovirus (CMV)-specifieke CTL op virale ladingen beoordeeld door wekelijkse reverse transcriptase-polymerase-kettingreactie
Tijdsspanne: Tot 1 jaar
|
Tot 1 jaar
|
|
|
Klinische respons op CTL-infusies
Tijdsspanne: Met 6 weken en 3 maanden
|
Met 6 weken en 3 maanden
|
|
|
Aantal deelnemers met behandelingsgerelateerde bijwerkingen zoals beoordeeld door CTCAE v4.0".
Tijdsspanne: Tot 1 jaar
|
Tot 1 jaar
|
|
|
Antiviral activity defined as response to viral load
Tijdsspanne: At day 28
|
Complete response, partial response, stable disease or progression will be defined and proportion of each outcome will be calculated. |
At day 28
|
|
Overall survival
Tijdsspanne: From last CTL infusion till death, assessed at 6 and 12 months
|
Kaplan-Meier survival function will be used to estimate the survival probability. |
From last CTL infusion till death, assessed at 6 and 12 months
|
|
Risk for chronic GVHD
Tijdsspanne: At 6 and 12 months post CTL infusion
|
Survival analysis method will be applied. Time to chronic GVHD will be defined from time of the last CTL infusion to the onset of chronic GVHD, or the last clinical assessment date if no chronic GVHD. Cumulative incidence of chronic GVHD at 6 and 12 months will be estimated. |
At 6 and 12 months post CTL infusion
|
|
Systemic infections
Tijdsspanne: Within 6 months of CTL infusion
|
Will be reported by etiologic agent, site of disease, date of onset, and severity. |
Within 6 months of CTL infusion
|
|
Secondary graft failure
Tijdsspanne: 30 days post-CTL infusion
|
Proportion of secondary graft failure for both populations will be assessed at 30 days post CTL infusion will be calculated and 95% confidence intervals will be estimated accordingly. |
30 days post-CTL infusion
|
|
Viral reactivations
Tijdsspanne: Up to 6 months
|
Proportion of viral reactivations within 6 months will be calculated and 95% confidence intervals will be estimated accordingly. |
Up to 6 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Sumithira Vasu, MBBS, Ohio State University Comprehensive Cancer Center
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- OSU-17199
- NCI-2018-01412 (Register-ID: CTRP (Clinical Trial Reporting Program))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .